Author: CWS, erstellt am: 2010/05/10, Last modification: 2019/09/17

CWS-Guidance CWS-guidance for risk adapted treatment of soft tissue sarcoma (STS) and soft tissue tumours in children, adolescents, and young adults.
Disease Soft tissue tumours
Type Therapy-guidance
Problem / Objectives

The CWS-Study-Grpup provides all participating centres of the registry SoTiSar with a threrapy guideline. The" CWS-Guidance" is a guideline for the teatment of patients with a soft-tissue-tumour or sarcoma with the following tumourgroups or clinical situations:

Localized rhabdomyosarcoma: Based on the results of the European Soft Tissue Study Group (EpSSG) a new risk grouping system and a standard-therapy for patients with local RMS has been developed in the year 2004 as a Pan European consenus. This therapy, which is actually the best known, is part oft the CWS-Guideline.
In addition the CWS-Guidline provides therapy-guidelines for:

Other local "RMS-like" tumours: Extraosseous Ewing tumours, Peripheral primitive neuroectodermal tumour, Synovial sarcoma, Undifferentiated sarcoma

Non-rhabdomyosarcoma ("NRSTS")

Metastatic patients

“Second line” Chemotherapy: Possible fpr patients with only partial-response, stable desease or relapsed desease

Fibromatosis and Myxofibromatosis

Pleuropulmonary Blastoma: (in cooperation with the International Pleuropulmonary Blastoma Registry, USA, CWS-Coordinator Dr. Sylvia Kirsch)

Gastrointestinal Stroma Tumour and Dermatofibrosarcoma protuberans: (in cooperation with the European Working Group on Pediatric GISTs, CWS-coordinator PD Dr. Martin Benesch, Graz, Österreich)

The CWS-Guidance contains todays best known, standardised therapy-guideline for different soft-tissue tumours and sarcoma. It is based on the results of the european trials CWS-81, 86, 91, 96 and 2002P and other international trials. For patients with RMS a therapy is recommanded, which was developed in 2004 with experts of the "European paediatric Soft Tissue Study Group" as a european standard.

Therapy / Study arms

The therapy-arms will be stratified accordingly to the tumourtype (Rhabdomyosacoma, RMS-like tumours, Non-RMS-like tumours, other soft-tissue-tumours) and the risk-factors (histology, post surgical stage, tumour site, node involvement, initial tumour size and patients’ age).
Patients with a local High-risk Rhabdomyosarcoma, who reached a complete remission after a multimodal chmeotherapy can take part in the randomized, proospective, multinational trial CWS-HR 2007 with the objective to improve the therapy.

Inclusion Criteria

Target population for the treatment :

  • Patients with pathologically confirmed localized or metastasized soft tissue tumour.
  • Diagnostic material available for pathology review.
  • Age less than 21 years (20 years and 364 days)*.
  • * exception: in case of rhabdomyosarcoma, patients older than 21 years of age can be included as well.
Principal Investigator Prof. Dr. med. Ewa Koscielniak, Prof. Dr. med. Thomas Klingebiel

Dr. med. Monika Sparber-Sauer, Dr. med. Monika Scheer
Klinikum Stuttgart - Olgahospital
Klinik für Kinder- und Jugendmedizin - Pädiatrie 5,
Studienzentrale CWS
Kriegsbergstrasse 62
70174 Stuttgart
Telefon +49 (711) 278 73870
Fax +49 (711) 278 72749

Sponsoring The "Deutsche Kinderkrebsstiftung" supports the registry SoTiSaR and the CWS-2007 HR trial. The "Förderkreis Krebskranke Kinder Stuttgart e.V." supports the CWS-study coordination centre.